Download full-text PDF

Source

Publication Analysis

Top Keywords

milestones clinical
4
clinical pharmacology
4
pharmacology therapeutic
4
therapeutic drug
4
drug monitoring
4
monitoring antidepressants
4
milestones
1
pharmacology
1
therapeutic
1
drug
1

Similar Publications

Neonatal-perinatal medicine (NPM) fellowship training aims to educate fellows and enable them to move into successful independent neonatal practice. To reach this goal, every fellow must acquire a wide range of clinical, scholarly, and professional skills that require assessment and evaluation by the fellowship program. The assessment and evaluation of fellow progression and promotion must rely on a rigorous educational framework.

View Article and Find Full Text PDF

Exploring the Diagnostic Landscape: Portable Aptasensors in Point-of-care Testing.

Anal Biochem

January 2025

Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S. Nagar, Punjab 160062, India. Electronic address:

Aptamers, discovered in the 1990s, have marked a significant milestone in the fields of therapeutics and diagnostics. This review provides a comprehensive survey of aptamers, focusing on their diagnostic applications. It especially encapsulates a decade of aptamer, encompassing research, patents, and market trends.

View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of GLP-1 to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential.

View Article and Find Full Text PDF

Background: In recessive dystrophic epidermolysis bullosa (RDEB), complications like oesophageal strictures, hand contractures, cardiomyopathy and cutaneous squamous cell carcinoma (SCC) may develop, necessitating procedures such as oesophageal dilatation (OD), gastrostomy tube placement and hand surgery.

Objectives: To determine prevalence and age of onset of milestone events by RDEB subtype, specifically dysphagia, first OD, first gastrostomy tube, first hand surgery, cardiomyopathy, first SCC and death.

Methods: The Prospective Epidermolysis Bullosa Longitudinal Evaluation Study (PEBLES) is a register study of individuals with RDEB which records comprehensive EB- and non-EB-related health information.

View Article and Find Full Text PDF

Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.

Paediatr Drugs

January 2025

Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.

Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!